Dapagliflozin Lowers HbA1c, Systolic Blood Pressure and Serum Uric Acid in Patients With Type 2 Diabetes and Hypertension, Regardless of Class of Concomitant Antihypertensive Therapy

被引：0
|
作者：
Weber, Michael A.
Mansfield, Traci A.
Iqbal, Nayyar
Parikh, Shamik J.
Ptaszynska, Agata
机构：
来源：
CIRCULATION | 2014年 / 130卷
关键词：
Diabetes (Type II); Antihypertensive agents; Blood pressure; Hypertension; Glucose;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
13640
引用
收藏
页数：3
相关论文
共 50 条
  • [11] Achievement of HbA1c Goal and Body Weight and Systolic Blood Pressure Reduction When Treated with Dapagliflozin in Patients with Type 2 Diabetes Stratified by Disease Duration
    Yeh, Helen
    Katz, Arie
    Moran, Jason
    DIABETES, 2015, 64 : A313 - A313
  • [12] In vitro Interference of Uric Acid on Serum Fructosamine and Blood HbA1c
    Scolari, Rogerio
    Cassol, Jose P. E.
    Stein, Carolina S.
    de Carvalho, Jose A. M.
    Moresco, Rafael N.
    CLINICAL LABORATORY, 2022, 68 (04) : 858 - 861
  • [13] Efficacy of Dapagliflozin in Patients with Type 2 Diabetes Mellitus and Baseline HbA1c=9.0%
    Katz, Arie
    Yeh, Helen
    Sugg, Jennifer E.
    Parikh, Shamik J.
    List, James F.
    DIABETES, 2014, 63 : A284 - A285
  • [14] Dapagliflozin lowers blood pressure in hypertensive and nonhypertensive patients with type 2 diabetes
    Sjostrom, D.
    Johansson, P.
    Ptaszynska, A.
    List, J.
    Johnsson, E.
    DIABETOLOGIA, 2014, 57 : S332 - S333
  • [15] Achieving the composite endpoint of HbA1c, body weight, and systolic blood pressure reduction with canagliflozin in patients with type 2 diabetes
    Merton, Katherine
    Davies, Michael J.
    Vijapurkar, Ujjwala
    Inman, Doreen
    Meininger, Gary
    CURRENT MEDICAL RESEARCH AND OPINION, 2018, 34 (02) : 313 - 318
  • [16] Effect of Sex and Age on HbA1c, Body Weight, and Systolic Blood Pressure Reduction with Dapagliflozin
    Reusch, Jane E. B.
    Day, Danielle
    Wortzman-Show, Genevieve
    Katz, Arie
    Regensteiner, Judith G.
    DIABETES, 2015, 64 : A325 - A325
  • [17] HbA1c and systolic blood pressure variation to predict all-cause mortality in patients with type 2 diabetes mellitus
    Lee, Yun-Chi
    Chang, Chwen-Tzuei
    Chen, Rong-Hsing
    Wang, Tzu-Yuan
    Chen, Ching -Chu
    PRIMARY CARE DIABETES, 2024, 18 (02) : 146 - 150
  • [18] Achieving composite endpoint of HbA1c, body weight, and systolic blood pressure reduction with canagliflozin in patients with type 2 diabetes
    Merton, K.
    Davies, M. J.
    Vijapurkar, U.
    Inman, D.
    Meininger, G.
    DIABETOLOGIA, 2016, 59 : S345 - S345
  • [19] Contrasting Influences of Renal Function on Blood Pressure and HbA1c Reductions With Empagliflozin in Patients With Type 2 Diabetes and Hypertension
    Cherney, David
    Cooper, Mark
    Tikkanen, Ilkka
    Crowe, Susanne
    Johansen, Odd Erik
    Lund, Soren S.
    Woerle, Hans J.
    Broedl, Uli C.
    Hach, Thomas
    CIRCULATION, 2014, 130
  • [20] CONTRASTING INFLUENCES OF RENAL FUNCTION ON BLOOD PRESSURE AND HBA1C REDUCTIONS WITH EMPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES AND HYPERTENSION
    Cherney, D.
    Cooper, M.
    Tikkanen, I.
    Crowe, S.
    Johansen, O. E.
    Lund, S. S.
    Woerle, H. J.
    Broedl, U. C.
    Hach, T.
    JOURNAL OF HYPERTENSION, 2015, 33 : E53 - E53
12345